Initial Trial of Sanaria's Malaria Vaccine Yields Positive Results

Findings Provide Evidence that Vaccine is Safe and Potent

09-Sep-2011 - USA

Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria® PfSPZ Vaccine are published in Science.

"This is the first indication that a highly effective malaria vaccine may be available that can be used to eliminate Plasmodium falciparum malaria in geographically defined areas and prevent malaria in travelers," says Fred Binka, MD, PhD, Dean of the School of Public Health, University of Ghana.

An effective vaccine that prevents malaria infection is considered the only tool that will eventually conquer this disease. Such a vaccine must prevent infection in greater than 80% of recipients for 6-24 months in order to be suitable for elimination campaigns and protecting travelers.

High level protection has only been achieved in humans who were immunized by the bite of mosquitoes that inoculated live, sporozoite stage Plasmodium falciparum parasites that had been weakened by irradiation or drugs. Immune cells called cytotoxic or killer CD8+ T cells that are activated by the sporozoites are responsible for the protection against malaria after immunization with irradiated sporozoites.

It is not feasible to immunize large numbers of humans by bite of mosquitoes carrying sporozoites, and it was considered impossible to manufacture a sporozoite vaccine that met regulatory standards.

"Therefore, despite the high level protection induced by sporozoites administered by mosquito bite, before the breakthroughs reported in the Science paper, no human had ever been immunized with a sporozoite vaccine administered by needle and syringe," says Stephen L. Hoffman, MD, Sanaria's Chief Executive and Scientific Officer.

Sanaria has developed a unique manufacturing process that meets FDA standards to produce the Sanaria® PfSPZ Vaccine. The vaccine is composed of attenuated (weakened) malaria sporozoites that are the stage transmitted to humans by mosquitoes.

The vaccine was tested by a team of biomedical scientists from the U.S. Military Malaria Vaccine Program (Naval Medical Research Center and Walter Reed Army Institute of Research); University of Maryland Center for Vaccine Development; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Sanaria Inc.; PATH Malaria Vaccine Initiative; and Protein Potential, LLC. The principal findings and conclusions reported in Science are:

Sanaria® PfSPZ Vaccine was safe and well tolerated in this Phase 1 clinical trial in humans.
Sanaria® PfSPZ Vaccine administered in the skin by needle and syringe to humans was immunogenic and protective, but not nearly to the levels found after mosquito bite immunization.
Sanaria® PfSPZ Vaccine administered by intravenous injection to animals, triggered unprecedented high levels of malaria parasite-specific CD8+ T cells in the liver, the hallmark of protective immunity.
Sanaria® PfSPZ Vaccine is highly potent.

Based on these results, the PfSPZ Vaccine administered by intravenous injection will soon be assessed in a clinical trial at the Vaccine Research Center, NIAID, NIH in the United States. A trial in Tanzania is also being planned.

https://www.bionity.com/en/news/134283/initial-trial-of-sanaria-s-malaria-vaccine-yields-positive-results.html